| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Operating activities | ||||||||
Net loss | ||||||||
-14,905 | -11,331 | -11,391 | -9,232 | -7,293 | -4,868 | -7,901 | -6,674 | -4,403 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | ||||||||
54 | 50 | 50 | 43 | 31 | 23 | 28 | 27 | 27 |
Stock-based compensation | ||||||||
471 | 422 | 491 | 270 | 238 | 70 | 96 | 62 | 104 |
Gain (Loss) From Remeasurement Of Derivative Liability | ||||||||
-454 | - | - | - | 0 | - | - | - | - |
Non-cash interest expense | ||||||||
132 | 146 | 100 | 125 | 129 | 84 | 819 | 1,396 | 1,365 |
Non-cash research and development expense | ||||||||
557 | - | - | - | 0 | - | - | - | - |
Other non-cash transactions | ||||||||
100 | - | - | - | 0 | - | - | - | - |
Change in fair value warrant liability | ||||||||
- | - | - | - | - | -2,720 | 1,713 | 1,001 | -5 |
Change in fair value derivative liability | ||||||||
- | - | - | - | - | 0 | -359 | -155 | -162 |
Changes in operating assets and liabilities: | ||||||||
Other receivable | ||||||||
-337 | 650 | -598 | 511 | 437 | - | - | - | - |
Prepaid expenses and other assets | ||||||||
9,602 | 2,294 | -2,359 | 1,928 | 91 | 1,147 | -15 | 131 | -246 |
Accounts payable | ||||||||
-712 | 916 | -1,357 | 1,018 | 225 | 779 | 673 | -244 | 129 |
Accrued expenses and other current liabilities | ||||||||
-713 | 229 | 907 | 70 | -1,533 | 741 | 1,033 | 406 | -257 |
Deferred rent | ||||||||
- | - | - | - | - | 22 | 0 | -3 | -2 |
Net cash used in operating activities | ||||||||
-23,827 | -12,489 | -8,240 | -10,134 | -8,731 | -6,838 | -3,576 | -4,005 | -2,634 |
Investing activities | ||||||||
Purchases of property and equipment | ||||||||
558 | 136 | 395 | 345 | 84 | 88 | 3 | 22 | 6 |
Acquisition of intellectual property rights | ||||||||
100 | - | - | - | 0 | - | - | - | - |
Net cash used in investing activities | ||||||||
-658 | -136 | -395 | -345 | -84 | -88 | -3 | -22 | -6 |
Financing activities | ||||||||
Proceeds from development derivative liability | ||||||||
-10,000 | - | - | - | 0 | - | - | - | - |
Payments of deferred stock offering costs | ||||||||
116 | - | - | - | 0 | - | - | - | - |
Long-term borrowings, net | ||||||||
0 | - | 0 | 2,473 | 616 | - | - | - | - |
Proceeds from exercise of stock options | ||||||||
17 | 24 | 95 | 126 | 0 | - | - | - | - |
Repayments of long-term debt | ||||||||
0 | 0 | 0 | 0 | 938 | - | - | - | - |
Net cash provided by (used in) financing activities | ||||||||
9,901 | 4,879 | 64 | 48,907 | -322 | - | - | - | - |
Net decrease in cash and cash equivalents | ||||||||
-14,584 | - | - | - | -9,137 | - | - | - | - |
Net increase (decrease) in cash and cash equivalents | ||||||||
- | - | - | - | - | - | - | -2,032 | -2,640 |
Supplemental disclosure for cash flow | ||||||||
Cash paid for interest | ||||||||
246 | 219 | 166 | 93 | 98 | 99 | 71 | 51 | 39 |
Supplemental disclosure of cash flow information | ||||||||
Supplemental disclosure of non-cash investing and financing activities | ||||||||
Issuance of warrants in conjunction with development derivative liability | ||||||||
7,925 | - | - | - | 0 | - | - | - | - |
Accrued interest on term loan refinanced to principal | ||||||||
0 | 0 | 0 | 0 | 308 | - | - | - | - |
Issuance of warrants in conjunction with debt | ||||||||
0 | 59 | 0 | 87 | 209 | - | - | - | - |
Debt refinanced with new term loan | ||||||||
0 | 0 | 0 | 0 | 6,563 | - | - | - | - |
Initial recognition of operating lease right-of-use assets and operating lease liabilities | ||||||||
0 | - | 0 | 0 | 1,991 | - | - | - | - |
Accretion of redeemable convertible preferred stock | ||||||||
- | - | - | - | - | 0 | 62 | 17 | 16 |
Deferred stock offering costs in accounts payable | ||||||||
45 | - | - | - | 0 | - | - | - | - |
Purchases of property and equipment included in accounts payable and accrued expenses | ||||||||
1,031 | 817 | 0 | -5 | 11 | - | - | - | 10 |